drugset / Trial / NCT04254874

A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia

NCT04254874

Phase 4 Unknown 100 enrolled Tongji Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of two therapeutic schemes(abidol hydrochloride,abidol hydrochloride combined with interferon atomization)in the treatment of 2019-nCoV viral pneumonia, so as to provide reliable evidence-based medicine for the treatment of viral pneumonia caused by 2019-nCoV.

Timeline

Start
2020-02-01
Primary completion
2020-06-01
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2b Protein / enzyme biologic 45 ug Other
Background Umifenovir Small molecule 0.2 g

Indications